'Get with the Program!': Pharmaceutical marketing, symptom checklists and self-diagnosis

Social Science and Medicine

Volumn 73, Issue 6, 2011, Pages 825-832

  Ebeling, Mary ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

Diagnostic tools; Direct to consumer advertising; Disease state awareness; Drug marketing and branding; Self diagnosis; USA

Indexed keywords

ADALIMUMAB; ATORVASTATIN; BEVACIZUMAB; CLOPIDOGREL; ETANERCEPT; FLUTICASONE PROPIONATE PLUS SALMETEROL; INFLIXIMAB; RITUXIMAB; ROSUVASTATIN; VALSARTAN;

ADVERTISING; INTELLECTUAL PROPERTY RIGHTS; MARKETING; PHARMACEUTICAL INDUSTRY;

ADVERTIZING; ARTICLE; AWARENESS; CONSUMER ADVOCACY; CONSUMER HEALTH INFORMATION; DIAGNOSTIC PROCEDURE; DRUG INDUSTRY; DRUG MARKETING; DRUG PACKAGING; HEALTH PROMOTION; HUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PRESCRIPTION; PROFIT; RESOURCE ALLOCATION; SELF EVALUATION; SYMPTOM CHECKLIST 90;

CHECKLIST; DIAGNOSIS; DIAGNOSTIC SELF EVALUATION; DRUG INDUSTRY; FEMALE; HUMANS; MARKETING OF HEALTH SERVICES; PREMENSTRUAL SYNDROME; SOCIOLOGY, MEDICAL; UNITED STATES;

UNITED STATES;

EID: 80052260330     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2011.05.054     Document Type: Article

References (62)

1. Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. PLoS Med 2006, 3(4):e189.
2. Arnold M. For Pristiq, Wyeth deploys wind-up doll. Medical Marketing and Media 2009, 44(7):8.
3. Aronowitz R.A. Making sense of illness: Science, society and disease 1998, Cambridge University Press, Cambridge.
4. Aronowitz R.A. When do symptoms become a disease?. Annals of Internal Medicine 2001, 134(9 Part 2):803-808.
5. Arvidsson A. Brands: a critical perspective. Journal of Consumer Culture 2005, 5(2):235-258.
6. Bhatia S.C., Bhatia S.K. Diagnosis and treatment of premenstrual dysphoric disorder. American Family Physician 2002, 66(7):1239-1249.
7. Bowker G.C., Star S.L. Sorting things out: Classification and its consequences 2000, The MIT Press, Cambridge, Massachusetts.
8. Brown P. Naming and framing: the social construction of diagnosis and illness. Journal of Health and Social Behavior 1995, 35:34-52. (Health Module).
9. Busfield J. 'A pill for every ill': explaining the expansion in medicine use. Social Science & Medicine 2010, 70(6):934-941.
10. Caplan P.J. Premenstrual mental illness: the truth about sarafem. The Network News 2001, May/June.
11. Caplan P.J. Pathologizing your period. Ms. Magazine 2008, 18(3):63-64.
12. Clarke J.N., James S. The radicalized self: the impact on the self of the contested nature of the diagnosis of chronic fatigue syndrome. Social Science & Medicine 2003, 57(8):1387-1395.
13. Conrad P. Medicalization and social control. Annual Review of Sociology 1992, 18:209-232.
14. Conrad P. The medicalization of society: On the transformation of human conditions into treatable disorders 2007, The Johns Hopkins University Press, Baltimore.
15. Conrad P., Leiter V. From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation. Sociology of Health & Illness 2008, 30(6):825-838.
16. Copelton D.A., Valle G. "You don't need a prescription to go gluten-free": the scientific self-diagnosis of celiac disease. Social Science & Medicine 2009, 69(4):623-631.
17. Daw J. Is PMDD real?. Monitor on Psychology 2002, 33(9):58.
18. Warning letter: YAZ (drospirenone and ethinyl estradiol) Tablets 2008, Division of Drug Marketing, A. a. C, Food and Drug Administration, Division of Drug Marketing, Advertising and Communication (DDMAC), Washington DC.
19. Donohue J. A history of drug advertising: the evolving roles of consumers and consumer protection. Milbank Quarterly 2006, 84(4):659-699.
20. Dyer O. Disease awareness campaigns turn healthy people into patients. BMJ: British Medical Journal 2006, 332(7546):871.
21. Ebeling M. Beyond advertising: the pharmaceutical industry's hidden marketing tactics. PR Watch. 2008, February 21, 2008.
22. Fawcett J.A. Mood disorders work group. Diagnostic and statistical manual 5 (DSM-V) Development 2011, American Psychiatric Association, Arlington, VA. American Psychiatric Association (Ed.).
23. Fishman J.R. Manufacturing desire: the commodification of female sexual dysfunction. Social Studies of Science 2004, 34(2):187-218.
24. Foucault M. Right of death and power over life. The foucault reader 1984, 258-272. Pantheon, New York. P. Rabinow (Ed.).
25. Foucault M. Technologies of the self: A seminar With Michel Foucault 1988, Amherst University of Massachusetts Press, Amherst.
26. Freeman E.W., Kroll R., Rapkin A., Pearlstein T., Brown C., Parsey K., et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women's Health and Gender-Based Medicine 2001, 10(6):561-569.
27. Fugh-Berman A.J., Dodgson S.J. Ethical considerations of publication planning in the pharmaceutical industry 2008.
28. Gagnon M.-A., Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. Public Library of Science (PLoS) 2008, 5(1).
29. Giddens A. Modernity and self-identity: Self and society in the late modern age 1991, Stanford University Press, Stanford, Calif.
30. Greene J.A. Prescribing by numbers: Drugs and the definition of disease 2007, Johns Hopkins University Press, Baltimore, Maryland.
31. Greenslit N. Pharmaceutical branding: identity, individuality and illness. Molecular Interventions 2002, 2(6):342-345.
32. Greenslit N. Dep®ession and consum♀tion: psychopharmaceuticals, branding and new identity practices. Culture, Medicine and Psychiatry 2005, 29:477-501.
33. Healy D. The antidepressant era 1997, Harvard University Press, Cambridge, MA.
34. Healy D. Mandel Cohen and the origins of the diagnostic and statistical manual of mental disorders. History of Psychiatry 2002, 13(50):209-230. Third Edition: DSM-III.
35. Healy D. The latest mania: selling bipolar disorder. PLoS Med 2006, 3(4):e185.
36. Jutel A. Sociology of diagnosis: a preliminary review. Sociology of Health & Illness 2009, 31(2):278-299.
37. Public and physician views of direct-to-consumer prescription drug advertising. Kaiser public opinion spotlight 2008, Kaiser Family Foundation, Kaiser Family Foundation, Washington DC. M. Brodie (Ed.).
38. Lakoff A. Adaptive will: the evolution of attention deficit disorder. Journal of the History of the Behavioral Sciences 2000, 36(2):149-169.
39. Lakoff A. Diagnostic liquidity: mental illness and the global trade in DNA. Theory and Society 2005, 34:63-92.
40. Lupton D. Consumerism, reflexivity and the medical encounter. Social Science & Medicine 1997, 45(3):373-381.
41. Mechcatie E. FDA panel agrees flouxetine effective for PMDD. OB/GYN news 1999, Elvsevier Inc., Rockville, MD.
42. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role?. PLoS Medicine 2006, 3(4):461-465.
43. Mintzes B., Barer M.L., Kravitz R.L., Bassett K., Lexchin J., Kazanjian A., et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association Journal 2003, 169(5):405-412.
44. Mintzes B., Morgan S., Wright J.M. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS ONE 2009, 4(5):e5699.
45. Moynihan R. The marketing of a disease: female sexual dysfunction. BMJ: British Medical Journal 2005, 330(7484):192-194.
46. Moynihan R., Cassels A. Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients 2005, Nation Books, New York.
47. Moynihan R., Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med 2006, 3(4):e191.
48. Pharmaceutical pricing policies in a global market 2008, OECD, Organization for Economic Co-Operation and Development (OECD), Paris.
49. Offman A., Kleinplatz P.J. Does PMDD belong in the DSM? Challenging the medicalization of women's bodies. The Canadian Journal of Human Sexuality 2004, 13(1). 17(11).
50. Parry V. The art of branding a condition. Medical Marketing & Media 2003, 38(5):43-49.
51. Payer L. Disease-mongers: How doctors, drug companies, and insurers are making you feel sick 1992, Wiley, New York.
52. Prior L. Belief, knowledge and expertise: the emergence of the lay expert in medical sociology. Sociology of Health & Illness 2003, 25:41-57.
53. Prior, L., Evans, M. R., & Prout, H. (in press). Talking about colds and flu: The lay diagnosis of two common illnesses among older British people. Social Science & Medicine, Corrected Proof.
54. Rosenberg C.E. The tyranny of diagnosis: specific entities and individual experience. Milbank Quarterly 2002, 80(2):237.
55. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?. PLoS Med 2007, 4(9):e286.
56. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Social Studies of Science 2009, 39(2):171-198.
57. Stockl A. Complex syndromes, ambivalent diagnosis, and existential uncertainty: the case of Systemic Lupus Erythematosus (SLE). Social Science & Medicine 2007, 65(7):1549-1559.
58. Vassoler H. Americas pharma & healthcare insight. BMI's monthly market intelligence 2010, Business Monitor International, London. R. MacDonald (Ed.).
59. Does higher DTC spending result in positive patient-physician conversations? 2009, Verilogue Inc, Verilogue Inc., Horsham, PA.
60. The global pharmaceutical market 2010, VFA, Verband Forschender Arzneimittelhersteller (German Association of Research-Based Pharmaceutical Companies), Berlin. VFA (Ed.).
61. Wacquant L. Punishing the poor: The Neoliberal government of social insecurity 2009, Duke University Press, Durham and London.
62. Yonkers K.A., Halbreich U., Freeman E., Brown C., Endicott J., Frank E., et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Journal of the American Medical Association 1997, 278(12):983-988.